JP2005507880A5 - - Google Patents

Download PDF

Info

Publication number
JP2005507880A5
JP2005507880A5 JP2003528088A JP2003528088A JP2005507880A5 JP 2005507880 A5 JP2005507880 A5 JP 2005507880A5 JP 2003528088 A JP2003528088 A JP 2003528088A JP 2003528088 A JP2003528088 A JP 2003528088A JP 2005507880 A5 JP2005507880 A5 JP 2005507880A5
Authority
JP
Japan
Prior art keywords
compound
chemical formula
diluent
medicament
additive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003528088A
Other languages
English (en)
Japanese (ja)
Other versions
JP4540986B2 (ja
JP2005507880A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/029365 external-priority patent/WO2003024183A2/en
Publication of JP2005507880A publication Critical patent/JP2005507880A/ja
Publication of JP2005507880A5 publication Critical patent/JP2005507880A5/ja
Application granted granted Critical
Publication of JP4540986B2 publication Critical patent/JP4540986B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003528088A 2001-09-14 2002-09-16 ワートマニン類似体およびそれらを用いる方法 Expired - Fee Related JP4540986B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32214301P 2001-09-14 2001-09-14
US32213901P 2001-09-14 2001-09-14
PCT/US2002/029365 WO2003024183A2 (en) 2001-09-14 2002-09-16 Wortmannin analogs and methods of using same

Publications (3)

Publication Number Publication Date
JP2005507880A JP2005507880A (ja) 2005-03-24
JP2005507880A5 true JP2005507880A5 (enExample) 2006-01-05
JP4540986B2 JP4540986B2 (ja) 2010-09-08

Family

ID=26983283

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003528088A Expired - Fee Related JP4540986B2 (ja) 2001-09-14 2002-09-16 ワートマニン類似体およびそれらを用いる方法

Country Status (8)

Country Link
EP (1) EP1435941B8 (enExample)
JP (1) JP4540986B2 (enExample)
AT (1) ATE334671T1 (enExample)
AU (1) AU2002330029B2 (enExample)
CA (1) CA2458318C (enExample)
DE (1) DE60213633T2 (enExample)
MX (1) MXPA04002445A (enExample)
WO (1) WO2003024183A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7081475B2 (en) 2001-09-14 2006-07-25 Prolx Pharmaceuticals Corp. Wortmannin analogs and methods of using same
DE10219545A1 (de) * 2002-04-26 2003-11-06 Lang Florian Regulation der Apoptose
US7230139B2 (en) 2002-12-05 2007-06-12 Gemin X Biotechnologies Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents
CA2522980A1 (en) * 2003-04-23 2004-11-04 Wyeth Holdings Corporation Water soluble wortmannin derivatives
DE102004043463A1 (de) * 2004-06-09 2006-02-09 Heinz Voigt Mittel zur Krebsbekämpfung unter Verwendung von Schimmelpilzextrakten
AU2005333515B2 (en) * 2004-07-09 2012-05-10 Arizona Board Of Regents, Acting On Behalf Of The University Of Arizona Wortmannin analogs and methods of using same in combination with chemotherapeutic agents
TW200626610A (en) * 2004-10-13 2006-08-01 Wyeth Corp Analogs of 17-hydroxywortmannin as PI3K inhibitors
WO2006132675A2 (en) * 2004-12-20 2006-12-14 University Of South Florida Xiap-targeted prostate cancer therapy
EP1940386A4 (en) * 2005-09-01 2010-06-23 Beth Israel Hospital WORDMAN'S CONJUGATES AND USES THEREOF
US20070116736A1 (en) * 2005-11-23 2007-05-24 Argentieri Dennis C Local vascular delivery of PI3 kinase inhibitors alone or in combination with sirolimus to prevent restinosis following vascular injury
EP1965790B1 (en) * 2005-12-30 2011-12-07 Arizona Board of Regents, Acting on Behalf of The University of Arizona Metabolites of wortmannin analogs and methods of using the same
EP2012794B1 (en) * 2006-04-13 2014-09-17 The Trustees of Columbia University in the City of New York Compositions and intraluminal devices for inhibiting vascular stenosis
AU2011261243A1 (en) * 2010-06-04 2012-12-20 Oncothyreon Inc. Combination cancer therapies with wortmannin analogs
WO2011153495A1 (en) * 2010-06-04 2011-12-08 Oncothyreon,Inc. Cancer treatment with wortmannin analogs
US11197854B1 (en) 2018-11-14 2021-12-14 National Technology & Engineering Solutions Of Sandia, Llc Inhibitors for targeting flaviviruses
EP3903828A4 (en) 2018-12-21 2022-10-05 Daiichi Sankyo Company, Limited ANTIBODY-DRUG CONJUGATE AND KINAS INHIBITOR COMBINATION

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2302021A (en) * 1996-10-16 1997-01-08 Lilly Co Eli Inhibiting bone loss or resorption

Similar Documents

Publication Publication Date Title
JP2005507880A5 (enExample)
JP2004532209A5 (enExample)
JP2007522220A5 (enExample)
HRP20090281T1 (hr) 1,2,3,4-tetrasubstituirani indol za liječenje respiratornih bolesti
JP2005523922A5 (enExample)
EP1191614A3 (en) Luminescence device and metal coordination compound therefor
EA200401615A1 (ru) ИНГИБИТОРЫ АКТИВАЦИИ NF-kB
EA200200876A1 (ru) Алкилированные производные имидазопиридина
JP2007502904A5 (enExample)
JP2005509503A5 (enExample)
JP2025142197A5 (enExample)
JP2004502684A5 (enExample)
CA2458318A1 (en) Wortmannin analogs and methods of using same
ATE516031T1 (de) Verbindungen gegen krebs
JP2004527549A5 (enExample)
RU2003113145A (ru) Замещенные 5r1, 6r2-1, 3,4-тиадиазин-2, амины и содержащие их фармацевтические композиции в качестве фармакологически активных средств, обладающих антикоагулятным и антиагрегатным действием
JP2005513126A5 (enExample)
NO20070421L (no) Radiosensitiviserende middel
JP2007507467A5 (enExample)
JP2004523567A5 (enExample)
UY26416A1 (es) Compuestos
JP2003514806A5 (enExample)
JP2011518228A5 (enExample)
RU2002111465A (ru) Смесь изомеров 2-моноэтаноламино-5(6)-нитро-1-(тиетанил-3)бензимидазола
RU2004121986A (ru) Промежуточные соединения для получения ингибиторов гликогенфосфорилазы